MedPath

Efficacy and Safety of 675-nm Laser for Dorsal Hand Rejuvenation

Not Applicable
Not yet recruiting
Conditions
Wrinkle
Interventions
Device: Redtouch
Registration Number
NCT06486727
Lead Sponsor
Mahidol University
Brief Summary

This study aimed to evaluate efficacy and safety of 675-nm laser for dorsal hand rejuvenation in Thai patients. Twenty-six subjects aged 50 to 65 years diagnosed with wrinkle and solar lentigines on both dorsums of hands were included and treated with RedTouch for 3 times every 4 weeks. Then, they were follow up at 3 and 6 months after the final treatment. The measurement of 5-point Global Aesthetic Improvement Scale scores by physicians and subjects were conducted. Moreover, pigmentation level, wrinkle and texture were also recored using Antera. Elasticity was measured using Cutometer.

Detailed Description

RedTouch parameter included Moveo, power 5 W, Energy/DOT 500 mJ/DOT, then Standard, power 4 W, spacing 2000 μm, 1 pass per side.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
26
Inclusion Criteria
  • Subjects diagnosed with wrinkles and solar lentigines on both dorsum of hands
Exclusion Criteria
  • Pregnant or lactation
  • Sugjects with a history of allergy to near-infrared wavelength or photosensitizing agents
  • Subjects who have been treated with any kind of energy-based device on both dorsum of hands 6 months prior to the inclusion
  • Subjects who have been injected with filler, or platelet-rich plasma on both dorsum of hands on their faces 6 months prior to the inclusion
  • Active skin infections
  • History of hypertrophic scars or keloids

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
675-nm laser (RedTouch)RedtouchParamete: Moveo, power 5 W, Energy/DOT 500 mJ/DOT then Standard, power 4 W, spacing 2000 μm, 1 pass per side for 4 times with 4-week interval
Primary Outcome Measures
NameTimeMethod
The change in pigmentation level, wrinkle and textureBaseline, 4, 8, 12 weeks after the first treatment and 3, 6 months after the last treatment

Using Antera®

Secondary Outcome Measures
NameTimeMethod
The change in elasticityBaseline, 4, 8, 12 weeks after the first treatment and 3, 6 months after the last treatment

Using Cutometer®

Overall improvement by physicians and patients4, 8, 12 weeks after the first treatment and 3, 6 months after the last treatment

5-point GAIS

Adverse events4, 8, 12 weeks after the first treatment and 3, 6 months after the last treatment

Side effects

Pain scoreBaseline, 4, 8, 12 weeks after the first treatment

Visual analog scale (0-10; no pain-worst pain possible)

© Copyright 2025. All Rights Reserved by MedPath